Researchers
reporting in The Lancet on the LiGHT Study concluded that a
change in the clinical practice pattern of how we treat glaucoma should be
implemented so that glaucoma laser
treatment was a first choice treatment, rather than eye drops which is the
typical approach to glaucoma treatment. The LiGHT Study compared eye drops to
glaucoma Selective Laser Trabeculoplasty (SLT) treatment in terms of lowering
intraocular pressure, health related quality of life, cost and cost
effectiveness. The data was gathered and analyzed and concluded that Selective Laser
Trabeculoplasty (SLT) should be offered as a first-line treatment for open
angle glaucoma and ocular hypertension, supporting a change in clinical
practice.
If
you or someone you know is at risk for glaucoma, has ocular hypertension or is
being treated for glaucoma, please be certain you have regular eye exams with
glaucoma testing to prevent vision loss. Ask your eye doctor about treatment
options such as SLT for glaucoma when you schedule your exam at Doctor &
Associates-203-227-4113.
